Illumina (ILMN)
(Delayed Data from NSDQ)
$114.72 USD
+7.93 (7.42%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $114.94 +0.23 (0.20%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Illumina, Inc. [ILMN]
Reports for Purchase
Showing records 241 - 260 ( 361 total )
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 - Slight Revenue Wobble Like We Had Suspected - Encouraged By Strong Pipeline Commentary - We Are Buyers On the Weakness - Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Preview - Cautious on System Sales Given Our Lack of Visibility - Consumables Story Likely Strong - LT Thesis Intact - Raising PT to $250
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
High Likelihood of ACOG Average Risk NIPT Recs in the Next Few Days, According to Source - Potential Positive Catalyst for Stock - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
High Likelihood of ACOG Average Risk NIPT Recs in the Next Few Days, According to Source - Potential Positive Catalyst for Stock - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Recap - NIPT Momentum Drives Sales Strength - Opex Leverage Drives Healthy EPS Beat - Maintaining OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Preview - Tweaking Estimates Due to Fx - NIPT Dr. Checks More Encouraging Post ACOG Comments - Maintaining OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Natal Checks: Noncommittal ASHG/ESHG Recs Slightly Negative for All Comers? NIPT Story - Positive ACOG Recs Not Likely a 2015 Event - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Illumina, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Natal Checks: Noncommittal ASHG/ESHG Recs Slightly Negative for All Comers? NIPT Story - Positive ACOG Recs Not Likely a 2015 Event - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z